{"id":13432,"date":"2010-11-10T10:30:00","date_gmt":"2010-11-10T09:30:00","guid":{"rendered":"http:\/\/www.fedaiisf.it\/dompe-serve-un-piano-marshall-per-la-ricerca-in-italia\/"},"modified":"2010-11-10T10:30:00","modified_gmt":"2010-11-10T09:30:00","slug":"dompe-serve-un-piano-marshall-per-la-ricerca-in-italia","status":"publish","type":"post","link":"https:\/\/www.fedaiisf.it\/en\/dompe-serve-un-piano-marshall-per-la-ricerca-in-italia\/","title":{"rendered":"Domp\u00e8, we need a Marshall Plan for research in Italy"},"content":{"rendered":"
<\/font><\/div>\n

<\/font><\/p>\n

Cernobbio (CO). (Adnkronos) \u2013 A Marshall plan is needed for research in Italy. With the collaboration of all the protagonists of the sector: industry, institutions, public and private research bodies. And we need to focus a lot on innovation, providing, for example, privileged regulatory paths for the authorization of innovative medicines. This was asked by Sergio Domp\u00e9, president of Farmindustria who spoke at the national conference on health research, which has just closed in Cernobbio.<\/font><\/div>\n

November 10, 10:42 am<\/em><\/p>\n

\"\" Villa Grass<\/em><\/p>\n

Chiesi Group: reconfirmed as 1* in Italy for research and development<\/strong><\/h1>\n

Dowjones<\/font><\/p>\n

MILAN (MF-DJ) \u2013 For the 2nd consecutive year, the Chiesi group confirmed its place in 1st place among Italian investors in Research and Development in the pharmaceutical sector, 8th place in the ranking of the major national groups in each sector and 14th among pharmaceutical multinationals throughout Europe. <\/font><\/p>\n

This is explained by the 2010 Scoreboard of European Industrial Investments in Research & Development, elaborated by the Joint Research Center (jrc) of the European Commission. The report, reads a note, was drawn up on the basis of the financial statements sent by the companies to the jrc and therefore does not represent all of the existing ones. <\/font><\/p>\n

Thanks to the investments made in 2009, equal to 132.6 million euros (+22.1% y\/y), the Parma-based group follows some of the major national companies in the ranking, such as Finmeccanica, Fiat, Telecom I. and Intesa Sanpaolo, while in the pharmaceutical sector it ranks behind large groups such as Sanofi-Aventis, GlaxoSmithKline, Astrazeneca and Boehringer Ingelheim in Europe. <\/font><\/p>\n

In 2009, investments by the Chiesi group reached 15.2% of turnover and are in contrast with the average figure for investments made by European companies (-2.6%). com\/ofb<\/font><\/p>\n

(END) Dow Jones Newswires<\/font><\/p>\n

November 08, 2010 11:59 AM ET (4:59 PM GMT)          <\/font><\/p>\n

   \"\" Paolo Chiesi, Vice President and Director of Research and Development<\/em><\/font><\/p>\n

<\/font><\/p>\n

\"Chiesibis1\"<\/div>\n

Chiesi pharmaceuticals: 2009 turnover double-digit growth<\/font><\/h1>\n
A positive 2009 for the Chiesi Group, which confirms the growth trend recorded in recent years, both in Italy and internationally. Sales reached \u20ac872 million with a growth of 16.5% on 2008<\/strong>. In addition to the traditional perimeter of the group, the figure includes the result of Cornerstone Therapeutics, an American company acquired in 2009 and consolidated in terms of turnover for the August-December period. The Italian market has contributed to the result for 34.6%, with a growth of 5.2% compared to 2008<\/strong>. Over the 65% was made on international markets. \u201cThese results are f<\/p>","protected":false},"excerpt":{"rendered":"

Cernobbio (Co). (Adnkronos) – Serve un piano Marshall per la ricerca in Italia. Con la collaborazione di tutti i protagonisti del settore: industria, Istituzioni, enti di ricerca pubblici e privati. E bisogna puntare molto sull’innovazione, prevedendo, per esempio, percorsi regolatori privilegiati per l’autorizzazione dei farmaci innovativi. Lo chiede Sergio Dompé, presidente di Farmindustria intervenuto alla …<\/p>","protected":false},"author":1,"featured_media":9846,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[90],"tags":[],"class_list":["post-13432","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-fedaiisf-archivio-storico"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13432","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/comments?post=13432"}],"version-history":[{"count":0,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/posts\/13432\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media\/9846"}],"wp:attachment":[{"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/media?parent=13432"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/categories?post=13432"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.fedaiisf.it\/en\/wp-json\/wp\/v2\/tags?post=13432"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}